-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on SAB Biotherapeutics, Raises Price Target to $12

Benzinga·06/15/2026 12:59:33
Listen to the news
Leerink Partners analyst Thomas Smith maintains SAB Biotherapeutics (NASDAQ:SABS) with a Outperform and raises the price target from $7 to $12.